Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Breast Cancer Metastatic × Aromatase Inhibitors × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 55 Polycystic Ovary Syndrome 3 Neoplasms, Hormone-Dependent 3 Neoplasm Metastasis 2 Carcinoma, Lobular 2 Carcinoma, Intraductal, Noninfiltrating 2 Carcinoma, Ductal, Breast 2 Breast Cancer Female 2 Advanced Breast Cancer 2 Sexuality 1 Osteoporosis 1 Luminal B/HER2-negative Breast Cancer 1 Leiomyoma 1 Infertility 1 Hormone Receptor Positive Breast Carcinoma 1 Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer 1 Fractures, Bone 1 Estrogen Receptor and/or Progesterone Receptor Positive 1 Endometrial Neoplasms 1 Bulbo-Spinal Atrophy, X-Linked 1 Breast Neoplasms, Male 1 Breast Diseases 1 Breast Carcinoma In Situ 1 Breast Cancer Metastatic 1 Bone Diseases, Metabolic 1 Arthralgia 1 Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Fulvestrant 5 Letrozole 4 exemestane 3 Anastrozole 3 ribociclib 2 dalpiciclib 2 apatinib 2 Trastuzumab 2 Gemcitabine 2 Docetaxel 2 Capecitabine 2 tusamitamab ravtansine 1 trastuzumab deruxtecan 1 pyrotinib 1 patritumab deruxtecan 1 palbociclib 1 olaparib 1 nirogacestat 1 margetuximab 1 irinotecan sucrosofate 1 fluzoparib 1 abemaciclib 1 Zoledronic Acid 1 Vinorelbine 1 Tamoxifen 1 Paclitaxel 1 Neoadjuvant Therapy 1 Liposomes 1 Irinotecan 1 Ga(III)-DOTATOC 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02511639 2020-12-03

MAIN-A

Istituto Oncologico Veneto IRCCS

Phase 3 Completed

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡